Seeking Alpha

Trius Therapeutics (TSRX +0.7%) says the FDA has designated it's Phase 3 antibiotic candidate,...

Trius Therapeutics (TSRX +0.7%) says the FDA has designated it's Phase 3 antibiotic candidate, tedizolid phosphate, as a Qualified Infectious Disease Product for acute bacterial skin and skin structure infections, as well as for hospital-acquired/ventilator-associated bacterial pneumonia. The designation enables the company to benefit from certain incentives for the development of new antibiotics, including priority review and fast-track status.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs